(NYSE: NVO) Novo Nordisk (Ozempic)'s forecast annual revenue growth rate of 17.19% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 50.27%, and while it is forecast to beat the US market's average forecast revenue growth rate of 11.79%.
Novo Nordisk (Ozempic)'s revenue in 2025 is $38,876,867,816.On average, 2 Wall Street analysts forecast NVO's revenue for 2025 to be $221,123,947,000,000, with the lowest NVO revenue forecast at $215,139,808,400,000, and the highest NVO revenue forecast at $227,108,085,600,000. On average, 2 Wall Street analysts forecast NVO's revenue for 2026 to be $258,431,523,900,000, with the lowest NVO revenue forecast at $248,871,361,200,000, and the highest NVO revenue forecast at $267,991,686,600,000.
In 2027, NVO is forecast to generate $276,746,137,800,000 in revenue, with the lowest revenue forecast at $276,746,137,800,000 and the highest revenue forecast at $276,746,137,800,000.